Financials data is unavailable for this security.
View more
Year on year Jinyao Pharmaceutical Co Ltd had relatively flat revenues (3.69bn to 3.78bn), though the company grew net income 230.60% from 35.41m to 117.05m. A reduction in the selling, general and administrative costs as a percentage of sales from 37.27% to 34.83% was a component in the net income growth despite flat revenues.
| Gross margin | 42.62% |
|---|---|
| Net profit margin | 5.19% |
| Operating margin | 5.41% |
| Return on assets | 2.93% |
|---|---|
| Return on equity | 4.45% |
| Return on investment | 5.06% |
More ▼
Cash flow in CNYView more
In 2023, Jinyao Pharmaceutical Co Ltd increased its cash reserves by 15.47%, or 94.20m. The company earned 783.01m from its operations for a Cash Flow Margin of 20.70%. In addition the company used 132.12m on investing activities and also paid 564.85m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.75 |
|---|---|
| Tangible book value per share | 2.31 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.26 |
|---|---|
| Quick ratio | 0.8002 |
| Total debt/total equity | 0.3615 |
|---|---|
| Total debt/total capital | 0.2205 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 770.00% and 230.56%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.69% |
|---|---|
| Div growth rate (5 year) | 9.21% |
| Payout ratio (TTM) | 70.15% |
| EPS growth(5 years) | -4.22 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 38.18 |
More ▼
